SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+)/PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial

Ciruelos, E. M.Ponce, J.Pernas Simon, S.Cortes, J.Cantos, B.Garate, E.Vega Alonso, E.Mele Olive, M.Martinez De Duenas, E.Montano Perianez, A.Martinez, N.Perello Martorell, A.Bermejo De las Heras, B.Arqueros Nunez, C.Fernandez, I.De la Haba Rodriguez, J.Oliveira, M.Gonzalez, X.Villagrasa Gonzalez, P.Prat, A.2023-05-032023-05-032022-05-050923-7534http://hdl.handle.net/10668/21908enSOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+)/PAM50 luminal metastatic breast cancer (BC): A randomized phase II trialconference outputopen access10.1016/j.annonc.2022.03.2271569-8041http://www.annalsofoncology.org/article/S0923753422006068/pdf792494100211